AR003928A1 - Comprimido del liberacion controlada - Google Patents

Comprimido del liberacion controlada

Info

Publication number
AR003928A1
AR003928A1 ARP960101520A AR10152096A AR003928A1 AR 003928 A1 AR003928 A1 AR 003928A1 AR P960101520 A ARP960101520 A AR P960101520A AR 10152096 A AR10152096 A AR 10152096A AR 003928 A1 AR003928 A1 AR 003928A1
Authority
AR
Argentina
Prior art keywords
polymer
tablet
pharmaceutical agent
rate
water
Prior art date
Application number
ARP960101520A
Other languages
English (en)
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of AR003928A1 publication Critical patent/AR003928A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Un comprimido de liberación controlada que incluye un agente farmacéutico y un excipiente. El excipiente incluye por lo menos 50% de polímero susceptiblede hincharse con agua y un lubricante. El polímero susceptible de hincharse con agua seselecci ona de manera que la velocidad de hinchado del polímero seaigual a la velocidad de disolución de polímero hinchado. Además, el excipiente puede incluir otros ingredientes tales como diluyentes, soportes, ligantes yotros compuestosfarmacológicamente inactivos. El polímero se selecciona teniendo en cuenta el agente farmacéutico, de manera que el comprimido sedisuelva completamente al mismo tiempo que se libera la última porción del agente farmacéutico.
ARP960101520A 1995-02-28 1996-02-26 Comprimido del liberacion controlada AR003928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39579295A 1995-02-28 1995-02-28

Publications (1)

Publication Number Publication Date
AR003928A1 true AR003928A1 (es) 1998-09-30

Family

ID=23564527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101520A AR003928A1 (es) 1995-02-28 1996-02-26 Comprimido del liberacion controlada

Country Status (11)

Country Link
EP (1) EP0821582B1 (es)
JP (1) JPH11509169A (es)
AR (1) AR003928A1 (es)
AT (1) ATE228829T1 (es)
AU (1) AU722741B2 (es)
CA (1) CA2213455A1 (es)
DE (1) DE69625189D1 (es)
MY (1) MY113429A (es)
PA (1) PA8388101A1 (es)
TW (1) TW431891B (es)
WO (1) WO1996026718A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
AU2004204825B2 (en) 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
KR20080080094A (ko) 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
WO2010026467A2 (en) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2758976C (en) 2009-04-20 2015-02-03 Alain Baron Chemosensory receptor ligand-based therapies
JP2013540156A (ja) 2010-10-19 2013-10-31 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
BR112013017411B1 (pt) 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Uso de uma composição compreendendo metformina ou um sal da mesma
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
AU2018375199B2 (en) 2017-12-01 2023-03-30 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Also Published As

Publication number Publication date
CA2213455A1 (en) 1996-09-06
ATE228829T1 (de) 2002-12-15
AU5171196A (en) 1996-09-18
MY113429A (en) 2002-02-28
AU722741B2 (en) 2000-08-10
TW431891B (en) 2001-05-01
EP0821582B1 (en) 2002-12-04
JPH11509169A (ja) 1999-08-17
WO1996026718A3 (en) 1996-10-10
DE69625189D1 (de) 2003-01-16
PA8388101A1 (es) 1997-09-30
EP0821582A2 (en) 1998-02-04
WO1996026718A2 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
AR003928A1 (es) Comprimido del liberacion controlada
AR003908A1 (es) Tableta de liberacion controlada
AR054782A2 (es) Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
KR880009639A (ko) 서방성 매트릭스 제형
ES2177592T3 (es) Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
MY124695A (en) Novel composition and use.
ES2172242T3 (es) Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua.
BR9708772A (pt) "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
ES2172782T3 (es) Medicamento a base de progesterona y de estradiol.
ES2065461T5 (es) Unidades de administracion de un farmaco de liberacion constante.
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
ATE219061T1 (de) Huperzin a analoge verbindungen
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
CZ15295A3 (en) Solid pharmaceutical dosing unit
DK0737069T3 (da) Deuterede aktive stoffer til transdermal administrering
ES2088956T3 (es) Estructura de tableta multifraccionable.
BG104527A (en) Formulations comprising dissolved paroxetine
BR0112878A (pt) Composição farmacêutica tendo atividade especìfica em água
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
BR9807365A (pt) Composição para destruir células epiteliais de pigmento retinal e células proliferativas
DK0688565T3 (da) Tablet, kapsel eller granulatkorn indeholdende desogestrel

Legal Events

Date Code Title Description
FB Suspension of granting procedure